Compare Marqeta Inc (MQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs TG Therapeutics Inc — how do they compare? Marqeta Inc trades at $18.09 (market cap $1.82B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4.5× Marqeta Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and TG Therapeutics Inc for 16 Days on average.
| MQ | TGTX | |
|---|---|---|
Market Cap | $1.82B | $8.16B |
Volume | 1,126,466 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $20.32 | $59.06 |
52-Week Low | $15.04 | $26.94 |
Typical Hold Time | 44 Days | 16 Days |
Enterprise Value | $1.13B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.11, up 6.15% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while revenue grew 23% year-over-year to $625M in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. However, valuation remains elevated with a P/E of 193.83 and negative EBITDA of -$19.27M despite improving cash flow trends.
Outlook remains mixed with analyst consensus at Hold (59% of ratings) and a $11.38 price target suggesting 37% downside. Key risks include contract renewals in Q3 2026 potentially slowing growth, while institutional sentiment is cautious despite technical strength. The stock's premium valuation requires sustained execution to justify current levels.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
